Mitochondrial uncoupling protein-2 and -3 (UCP2 and UCP3) may be involved in the modulation of resting metabolic rate and energy balance. To investigate their variability, the influence of this on the variability of energy expenditure, and potential regulatory factors of the expression of the corresponding genes, we measured their messenger ribonucleic acids (mRNAs) in muscle and white adipose tissue of lean, healthy men and correlated the abundance of these mRNAs (attomoles per g total RNA) with measures of resting metabolic rate, hormone levels (thyroid hormones, insulin, glucagon, leptin, and catecholamines), and fuels potentially involved in energy balance regulation. We also investigated whether the thiazolidinedione, troglitazone, stimulates UCP2 and UCP3 mRNA levels to follow up on the observation that this antidiabetic drug increases the levels of expression in cultured cells. We found UCP2 and UCP3 mRNA levels to be highly variable and poorly correlated with measures of energy expenditure and with most factors affecting energy balance. Only nocturnal urinary norepinephrine excretion could explain a significant fraction of the variability in both UCP2 and UCP3 expression in muscle, but not adipose tissue. Thyroid hormone and norepinephrine excretion were found to contribute to the variability of resting metabolic rate, but this could not be explained by an effect on UCP mRNAs. Troglitazone affected neither the expression of UCPs nor the hormones or the measures of metabolic rate investigated. In conclusion, our results show that the expression of UCP2 and UCP3 genes is quite variable in healthy males and that this variability does not explain that in resting energy expenditure, and suggest that sympathetic activity is an important potential regulator of the expression of these proteins in skeletal muscle. However, the data do not support the concept that regulation of the expression of these genes is the most important level of control of UCP3 and UCP2 functions, and other levels of control have to be invoked. (J Clin Endocrinol
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The mechanisms by which the cells of homeothermic animals generate heat are not fully understood (3) . A substantial fraction of thermogenesis simply represents the thermodynamic inefficiency of the biological machine and is closely related to ATP turnover. In addition, homeothermic animals can produce heat in a facultative manner by varying the thermodynamic efficiency with which ATP is generated.
Regulated uncoupling of phosphorylation is a well accepted mechanism of thermogenesis in brown adipose tissue, wherein an uncoupling protein (UCP1) or thermogenin can dissipate, in a regulated manner, the proton gradient generated across the inner mitochondrial membrane by respiration. The collapse of the proton gradient reduces ATP synthesis and accelerates respiration, with the attendant dissipation of energy as heat (see Refs. 4 and 5 for reviews). However, brown fat UCP1 could hardly explain the variability in resting energy expenditure (REE) in humans, as UCP1 is expressed only in brown adipose tissue, the amount of this tissue becomes limiting in adult humans, and the resting metabolic rate is by definition measured under conditions of thermoneutrality and in the fasting state, whereas UCP1 is activated by cold and food intake.
In recent years, Brand and colleagues suggested that a regulated proton leak could also take place in the mitochondria of other tissues (6, 7) . They further suggested that this is a physiological mechanism that contributes to maintain body temperature and could be regulated by thyroid hormone, among other factors, accounting for a significant fraction of the thermogenic effect of this hormone (8 -10) . However, the molecular mechanism mediating such a leak has remained elusive. Recently cloned UCPs, of broader tissue distribution (11) (12) (13) (14) (15) , have the potential to fill this gap in the hypothesis. Thus, UCP2 and UCP3 seem reasonable candidates to explain a proton leak in the mitochondria of several tissues, notably skeletal muscle, a tissue accounting for a significant fraction of the variability in REE (16) and where both UCPs are expressed.
Studies aimed at defining a role for UCP2 and UCP3 in the control of REE and energy balance have investigated the effect of spontaneous or experimental perturbations of energy balance on the expression of the corresponding genes. Although these studies do not negate a role for these proteins in energy balance, the results are hard to explain and even to reconcile with a role for these proteins in energy dissipation (see Ref. 17 and references therein). We have here taken the approach of investigating whether the variability in UCP2 and UCP3 gene expression could explain the variability in REE in the absence, to the extent possible, of the confounding influence of factors known to affect REE. A tight correlation between REE and measures of thermogenesis and the levels of UCP2 and UCP3 gene expression would establish a role for the regulation of these genes in the control of REE, thermogenesis, or both, whereas the lack of such a correlation would redirect attention to other levels of control, possibly the activities of these proteins. We thus examined the expression of these two genes in healthy, lean young males and correlated it with measures of resting metabolic rate and levels of hormones as well as fuels involved in energy balance. Another objective was to investigate the effect of the thiazolidinedione troglitazone on UCP2 and UCP3 messenger ribonucleic acid (mRNA) levels to follow up our recent observation that these antidiabetic drugs stimulate the expression of UCP2 in cell lines representing white and brown adipose tissues and skeletal muscle (18) .
Subjects and Methods Subjects
The study, approved by the research and ethics committee of the Jewish General, was performed in 18 healthy male volunteers recruited from advertisements placed in local newspapers. Subjects responding to the ad were screened after they were given full information on the study and consented in writing to participate. The study was limited to males to avoid the potentially confounding variability introduced by cyclic ovarian function. Exclusion criteria included any disease, condition, or drug that could affect either energy balance or the measurement of REE (e.g. anxiety or claustrophobia) as well as ages below 20 yr or greater than 45 yr or body mass index below 21 or above 26. Alcohol and caffeine usage were accepted if intake was equal to or less than the equivalent of two glasses of wine or two cups of coffee per day, respectively. Smokers and subjects involved in strenuous exercise regimens were also excluded. Qualifying subjects were submitted to a complete physical exam and laboratory screening for liver disease, diabetes, thyroid dysfunction, bleeding, and other hematological disorders. They were invited to participate if all tests results were normal. Pertinent information is presented in Table 1 .
Study protocol
Subjects were urged not to change their life style during the study. They reported after a normal night's sleep and in the fasting condition to a special study room in the Jewish General Hospital, between 0700 -0900 h. Blood and urine samples were obtained for basal studies. They then underwent training for the measurement of REE (see below) and returned within a few days for the formal study. This time, they brought a 12-h urine collection from the preceding night for the measurement of catecholamines and creatinine, to document the completeness of the urine collection.
Energy expenditure was measured using the Deltatrac ventilated hood indirect calorimeter (Summit Technologies, Oakville, Canada), calibrated, and manipulated as described previously (19) . Only the subject and the tester (M.B.) were present in an ad hoc pleasant, semidarkened, well ventilated, and thermoregulated (22-24 C) room. After the subject rested quietly for 30 min, a clear plastic hood was placed over the head and shoulders and ventilated with room air at 38 L/min. At an appropriate signal from the subject, oxygen and carbon dioxide sampling was begun. Data from the first 5 min of these measurements were discarded. CO 2 and O 2 volumes for each of the subsequent 15 min were averaged, converted to kilocalories using the Weir equation (20), and expressed on a per day basis. Average REE measured during the training session did not differ from the first formal measurement. The absolute variation from the training to the formal session was 1.83 Ϯ 0.8% (Ϯsem). Body temperature was monitored at the end of the REE measurement at several sites to calculate mean skin and mean body temperature. Core body temperature was monitored by a sensor inserted in the ear canal, placed in contact with the tympanic membrane (21) . Mean skin temperature was obtained from measurements on the chest, arm, thigh, and calf, calculated as described previously (22) . Mean body temperature, a weighted mean between skin and core temperature and a reflection of body heat production, was derived as reported previously (21, 23) .
After measurement of REE, each subject underwent a biopsy of quadriceps muscle (vastus lateralis) and the overlying sc adipose tissue. Fifty to 100 mg of each tissue were collected, immediately frozen over dry ice wrapped in a sheet of aluminum foil, transported to the laboratory within 30 min, and frozen at Ϫ80 C until processing. Biopsy was performed as follows. Skin and muscle fascia were infiltrated with 1% lidocaine; a small, 0.5-cm or smaller incision was made, and a 6-mm Bergstrom needle was introduced to collect a sample of sc adipose tissue; in a second pass, the needle was forced through the muscle fascia to collect a fragment of muscle. Each of two consecutive subjects was blindly assigned to take either troglitazone, two 300-mg tablets daily, or identical placebo tablets for 7 days. Both the drug and placebo were provided by Parke-Davis (Ann Arbor, MI). On day 6, the subjects returned for repeating REE measurements, and on day 7, they came for the last blood and urine measurements. At this time, they took the last dose of drug or placebo and, approximately 4 h later, underwent the second biopsy in the thigh not previously biopsied.
Biochemical analysis
Serum or plasma was analyzed for the various hormones indicated below, glucose, and fatty acids using standard, commercially available kits or automated methods routinely employed at the clinical chemistry 
RNA analysis
RNA from the tissue samples was extracted with guanidinium isothiocyanate, as previously described (24), and quantified by absorbance at 260 nm. It was then stored in small aliquots in diethylpyrocarbonatetreated water containing 0.4 U/l RNasin at Ϫ80 C until used. UCP2 and UCP3 mRNAs were quantified by a competitive RT-PCR assay established in our laboratory. The method uses a competitor with identical ends to the target RNA but with different internal sequence and cloned in a transcribable vector (PCR MIMIC kit, CLONTECH Laboratories, Inc., Palo Alto, CA). Using the same primers as the corresponding target RNA, this competitor generates in the PCR a product 25-30% different in size from target RNA or complementary DNA, clearly resolved from the product of the test RNA in agarose gel electrophoresis. The competitor can be added as RNA to the RT reaction or as DNA to the PCR. RT was routinely performed using random DNA primers. PCR was performed with the following sequence-specific primers: UCP2: sense, 5Ј-TCAGGCCCGGGCTGGAGGTGGTCGGA, corresponding to bases 526 -551 of mRNA; and antisense, 5Ј-CCTCTCGGGAAGTGCAG-GCAGCCATG, corresponding to bases 982-1007 of the mRNA (25) , located respectively in exons 5 and 8 of the gene (26); UCP3: sense, 5Ј-CCCAAAGGCGCGGACAACTCCAGCC; and antisense, 5Ј-GGGC-CACCATCTTTATCATACAGTCGAGGGG, corresponding, respectively, to bases 475-499 and 919 -949 of the human UCP3 mRNA (12) . The sense primer sequence spans the end of exon 3 and the beginning of exon 4, whereas the sequence complementary to the antisense primer is located in exon 6, between nucleotides 223 and 253 of this exon, upstream of the stop codon that generates the short UCP3 mRNA (UCP3 S ) splice variant (27) ; that is, our assay detects both splice variants, UCP3 S and UCP3 L .
Even though we optimized the RNA extraction procedure to eliminate significant traces of genomic DNA, we took additional precautions to avoid artifactual, confounding signals in the RT-PCR. Thus, the design of primers spanning separate exons caused any product derived from contaminating genomic DNA to be substantially larger than the products of the mRNAs. Besides, in each assay we ran sham RT reactions (reverse transcriptase omitted) to ensure the absence of products other than those from the reversed transcribed mRNAs. The assay was further validated and progressively simplified using RNA extracted from surgical specimens. Initially, graded amounts of the competitor RNA were added to constant size aliquots of RNA samples, before the RT, to test the efficiency and reproducibility of the RT reaction. This proved to be quite reproducible from assay to assay and had minimal intraassay variability. Consequently, we performed additional measurements on previously analyzed RT products, now adding the competitor as DNA in graded amounts. The results were indistinguishable from those obtained by adding RNA competitor, as has been reported by others (28) . This avoided the need for performing multiple RT reactions, with various amounts of the corresponding competitors, for each RNA sample. RNA integrity and homogeneity in sampling were systematically confirmed by ribosomal RNA quantity and appearance as well as ␤-actin mRNA abundance. Lastly, to avoid interassay variations, all RNA samples from a tissue were assayed for a given mRNA in the same assay. Results are expressed as attomoles of the corresponding mRNA per g total RNA.
Statistical analysis
Results are expressed as the mean Ϯ sem. Paired Student's t test was used for comparison of values obtained from the same individual in separate occasions. To investigate factors potentially affecting the mRNA levels of the UCPs, we performed linear regression analysis using the initial set of values or the changes occurred between paired measurements. We used Prism 3.0 software (GraphPad Software, Inc., San Diego, CA) for statistical analysis. Data were tested for normal distribution, and Spearman rank test correlation was used in the rare event of a nonnormally distributed set of data. Results were considered statistically significant if the appropriate two-tailed P Ͻ 0.05.
Results
The anthropometric and most relevant laboratory values are shown in Table 1 . The mean age was 29.7 yr (range, 21-43 yr), and subjects were within the target body mass index, with an average of 23.3 (range, 21.5-25.6). All variables investigated were within the corresponding reference ranges.
The UCP2 and UCP3 mRNA levels are shown in Fig. 1 and Table 2 along with their descriptive statistics. Our muscle UCP2 mRNA value is almost identical to that reported by Millet et al. (29) , whereas the UCP3 and adipose tissue UCP2 mRNA values were somewhat lower. However, Bao et al.
reported lower values for UCP3 than UCP2 mRNA in muscle (30) . These differences may be due to bias in the assessment of the competitor in the RT-PCR assays and are of no consequence for internal comparisons. The levels of three mRNAs, namely, muscle UCP3 and UCP2 as well as adipose tissue UCP2, where highly variable among individuals (Table 2), with se between 10 -20% of the mean, a range of values of about 5-to 10-fold, and coefficient of variations of 50 -70%. This large variability among individuals can be visually appreciated in Fig. 1 . It is also evident that troglitazone treatment had no consistent effect on any of the three mRNAs (nor did it affect any of the other variables measured). In the paired analysis, the mean differences between the pre-and posttreatment measurements were not significantly different from zero (Table 3) . However, values changed markedly and randomly between the two measurements in the majority of the subjects, whether they were given placebo or troglitazone, indicating that levels of these messenger RNAs are also highly variable within individuals. Accordingly, there was no correlation between pre-and posttreatment values, whether segregated by treatment or pooled, except for adipose tissue UCP2 mRNA in the control group (r ϭ 0.50; P Ͻ 0.05; Table 3 ). In contrast, despite ranges of interindividual variation as large as 18-fold for some of the other variables measured, there was a significant correlation between basal and posttreatment values of TSH, free T 4 , free T 3 , insulin, and leptin as well as glucose (not shown). Such a correlation was not found for cortisol, nocturnal urinary excretion of NE, or FFA (not shown).
The hormones levels depicted in Table 1 as well as glucose and FFA concentrations are all related to energy balance and could potentially affect the expression of UCPs. It has also been reported that in obese subjects UCP2 expression is correlated with BMI and fat mass (29, 31) , and that fasting (29) and FFA (32) can affect the expression of this UCP as well as UCP3 in humans and experimental models. Of the measurements made in our healthy study subjects (Table 1) , only nocturnal NE excretion was significantly correlated to the abundance of both UCP2 and UCP3 mRNA in skeletal muscle, but not in sc white adipose tissue (Fig. 2) .
Measures of thermogenesis with their descriptive statistics are presented in Table 4 . REE was 1444 Ϯ 31.8 Cal/day, with a coefficient of variation of 9.3%. Respiratory quotient was 0.86 Ϯ 0.06, reflecting a mixed diet. Mean body temperature, which is a weighted mean of core body temperature and body surface temperature and a function of heat production (22) , was 34.7 Ϯ 0.15 C. The individual data are presented in Fig. 3 to show the intra-and interindividual variabilities and FIG. 1. UCP3 and UCP2 mRNA in muscle and adipose tissue of healthy males before and after treatment with troglitazone for 7 days. Subjects were treated with troglitazone or placebo as described in Materials and Methods. Measurements in one subject are connected by lines. Results of the statistical analyses are presented in Table 3 . For any mRNA, neither treatment nor group assignment had a statistically significant effect. Descriptive statistics for pooled UCP mRNA values are shown in Table 2 . See text for details. the lack of effect of troglitazone. Of all three values, the most constant within individuals was REE, as reflected by a significant correlation between the basal and posttreatment results (r ϭ 0.61; P Ͻ 0.008), whereas there was no significant correlation between the two other values in the paired comparison. None of these measures of metabolic rate and thermogenesis correlated to the level of expression of UCP2 or UCP3 (data not shown).
Of all factors that could affect metabolic rate and thermogenesis presented in Table 1 , only nocturnal urinary excretion of NE correlated significantly with REE. Because of the homogeneity of the sample, this correlation was not affected when NE was normalized to creatinine excretion. Furthermore, to avoid the influence of anthropometric variables, such as lean body mass or body surface area, on REE and focus only in the intraindividual variation, we examined the percent change in REE between the first and second individual measurements and related it to simultaneous changes in possibly causative factors. As troglitazone had no effect on any of these measurements analyzed, the data for all 18 individuals were pooled. As shown in Fig. 4 , the intraindividual changes in REE between the first and second measurements correlated significantly with the corresponding changes in free T 4 and NE.
Discussion
For reasons indicated in the introduction, we took the approach of investigating whether the variability of UCP2 and UCP3 gene expression could explain the variability of measures of energy expenditure and thermogenesis, avoiding the confounding influence of factors known to affect the latter, such as age, sex, and body composition. We found that the level of expression of UCP2 mRNA in muscle and adipose tissue and that of UCP3 mRNA in muscle are highly variable both among individuals and in the same subject, and could not explain the variability observed in surrogates of energy expenditure and thermogenesis. Although many hormones and fuel levels that could possible affect the level of expression of the these proteins also exhibited a large interindividual variation, the intraindividual variability of many of them was not as much as that of UCPs. Notably among these were TSH, free T 4 , and free T 3 , insulin, and leptin, whereas urinary excretion of NE, serum cortisol, and FFA were quite variable in the same person, reflecting, perhaps, the responsiveness to external, rapidly changing influences. Of all of these possible regulators of the expression of the UCPs, only nocturnal NE could explain part of the variability. Interestingly, nocturnal NE excretion correlated with REE, and the intraindividual changes in REE occurring be- tween the two measurements correlated with the corresponding changes in both NE excretion and free T 4 concentrations. REE represents the basic energetic cost of living at rest (33) . It has been demonstrated to be quite variable, if not in absolute terms, in its meaning for energy balance. If one considers that the basic, minimum energetic cost of the most vital functions is a large fraction of REE, the variability of the excess, that is, the difference between this minimum energetic requirement and the actual REE, is even more striking (33) . The variability of this component seems to be genetically determined, as demonstrated in comparative studies within and between families and in subjects with variable shares of genetic material (1, 34) . Such variability is not irrelevant, as individuals with lower REE gain more weight during their lives (1, 35) . One can calculate that a sustained positive balance of as little as 50 Cal/day, which is well within the variability of REE of normal individuals, could result in the accumulation of more than 20 kg adipose tissue in 10 yr if stored.
As potential determinants of energetic cost of living, the novel UCPs are reasonable candidates to explain the variability in energy expenditure, but we found that the level of expression of the corresponding genes did not fulfill this expectation. An obvious question emerging from these findings is the extent to which the variability could be method- ological, as opposed to biological. As the methodology to measure these mRNAs was carefully standardized; the absence of degradation and the uniformity of a housekeeping gene mRNA, ␤-actin, in the samples were confirmed; the accuracy of the analytical techniques was optimized; and interassay variation was avoided, we are quite confident that the variability observed is truly biological. Our results show that the mRNA levels are highly variable, but that variability did not correlate with measures of energy expenditure or factors known to affect it, which suggest that if these two genes are indeed important in determining the variability of energy expenditure and thermogenesis, the relation takes place at another level, the protein abundance or its activity.
A question that we did not intend to address, because the tools are not available, is whether the variability in mRNA levels was reflected in the abundance of the corresponding proteins. Except for indirect evidence that there may be a correlation between UCP2 and its mRNA (36) , there are no other data. We return to this issue later. Nocturnal NE excretion accounted for a significant fraction of the variability of UCP mRNAs in muscle. Urinary NE excretion is more a reflection of sympathetic nervous activity than adrenal medulla secretion, and nocturnal NE excretion is less influenced by daily hazards, reflecting better the sympathetic tone of the individual. The data suggest, therefore, that sympathetic tone on skeletal muscle could be an important factor in the regulation of expression of these UCP genes. It has been shown in animals that sympathetic activity stimulates the expression of UCP3 and UCP2 in muscle (37, 38) , and we have found the NE increases severalfold the level of UCP2 mRNA in rat L6 muscle cells (unpublished observations). On the other hand, NE excretion correlated with REE and the differences between the two measurements in NE excretion correlated with the changes in REE, underscoring the importance of the sympathetic nervous system to the regulation of metabolic rate. Therefore, this system controls both the synthesis of these UCPs and REE, but the data do not support the conclusion that the levels of expression of the UCP genes in muscle and REE are related. An inclusive hypothesis is that sympathetic activity controls both the expression of the genes and the activity of the UCPs, as it does with UCP1 in brown adipose tissue. In the latter, changes in the protein follow the mRNA with substantial delay (39 -41) , but this delay is compensated by stimulation of the activity of the protein through the NE-induced release of fatty acids (5) . A constraint from the experimental design could have obscured a correlation between changes in UCP expression and REE. Thus, to avoid the effect of stress of the biopsies on REE and NE excretion and to maximize the possibility of seeing a short term effect of troglitazone on UCPs mRNAs, the second biopsy and REE measurement were performed more than 24 h apart. Nonetheless, the alternative that sympathetic activity influences REE predominantly via other mechanisms cannot be excluded.
Another major factor affecting energy expenditure is thyroid hormone, a role acquired by this hormone with the advent of homeothermy (42) . We have previously shown in humans that REE is very sensitive to minor changes in the availability of T 4 (43) . Here, we report that the basal level of UCP2 and UCP3 expression does not correlate to TSH, free T 4 , or free T 3 , but found instead that the changes in REE observed between two consecutive measurements correlate well to changes in the free T 4 concentration. TSH, free T 3 , and free T 4 varied widely among study subjects, but varied much less within individuals, as reflected by the high level of correlation between consecutive measurements noted above. Of the three, the range of differences between the two measurements for TSH and free T 3 were respectively 1-2 mU/L and 1-2 pmol/L, whereas in the case of free T 4 the differences spanned 7-8 pmol/L. The changes in TSH and free T 3 are probably below the sensitivity of the assays, whereas in the case of free T 4 they were wider. It is possible that the differences in free T 4 were indeed due to minor variations in TSH or other factors perturbing the exchange between the large pool of bound hormone and the small pool of free T 4 . Regardless of the mechanism, these results underscore the role of thyroid hormone in regulating REE (43) . Although neither the levels of free T 4 nor its changes within an individual correlated to the mRNA levels of UCP2 or UCP3, we do not believe that our findings contradict experimental studies showing that thyroid hormone affects the expression of muscle UCP3 and heart UCP2 in rats (37, 44 -46) , because such studies were performed in models with profound alterations of the thyroid status, whereas the data reported here are from euthyroid, healthy subjects. As with NE, these observations suggest that wide fluctuations in thyroid hormone, such as those occurring in the dysthyroid states, can affect the level of expression of the UCP genes, whereas smaller, physiological fluctuations could affect the activities of these proteins, but also, as with NE, thyroid hormone could, alternatively, affect REE via unrelated mechanisms.
An additional objective of the present studies was to investigate whether the acute administration of the thiazolidinedione, troglitazone, increased the mRNA levels of the novel UCPs, particularly UCP2. This part of the study was motivated by our observation that thiazolidinediones rapidly and vigorously stimulate UCP2 expression in cells representing muscle as well as brown and white adipose tissues (18) , and it was important to pursue, because the documentation of such an effect in humans could point to potential relations between the UCPs and insulin sensitivity. Because of the rapidity of the effect in cells (2-4 h), we administered the drug for only a few days, and the last dose was taken within 4 h of the biopsy of white adipose tissue and muscle in case there could be a rapid, short-lived effect. Despite all precautions, we found no acute effect of troglitazone on the mRNA of either UCP, nor did we detect any effect on any of the measurements performed. These negative findings, however, do not exclude the possibility of an effect of thiazolidinediones on UCPs during longer administration or an effect in diabetic patients with insulin resistance. Indeed, the lack of influence of troglitazone on any of the variables studied suggests that in the absence of insulin resistance or hyperglycemia, these drugs have few, if any, detectable metabolic effects in humans, at least acutely.
In conclusion, we found that the level of expression of the UCP2 and UCP3 genes is quite variable, particularly in muscle, but this variability in gene expression does not explain the variability in surrogates of energy expenditure and thermogenesis in a homogeneous population of healthy, lean males. However, the expression of these two genes in muscle is significantly influenced by sympathetic activity, and the latter correlates, in turn, with energy expenditure. Fluctuations of thyroid activity also contribute to the variability in REE, but they do not affect the level of expression of the UCPs. These results suggest more complexity than anticipated in the regulation of the function of these proteins, the expression of the corresponding genes being just one level of control. It is possible that the activities of these proteins are under complex regulation, among other factors, by the sympathetic nervous system and thyroid hormones. On the other hand, the possibility that the function of UCP2 and UCP3 is not related to energy expenditure regulation and that sympathetic activity and thyroid hormone control REE by unrelated mechanisms cannot be excluded.
